Evidence map›Paper›PMID 42148067›Full record

ReviewFrontiers in immunology2026

A dynamic vascular-inflammatory-fibrotic loop in systemic sclerosis: an integrative immuno-vascular framework.

Razvan Constantin Ionitescu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Razvan Constantin IonitescuDepartment of Rheumatology, MedArt Cliniq, Râmnicu-Vâlcea, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Systemic sclerosis (SSc) is characterized by a complex and heterogeneous interplay between vascular dysfunction, immune activation, and progressive fibrosis. Despite advances in molecular characterization, therapeutic responses remain inconsistent and often transient, suggesting that disease persistence arises from dynamic interactions rather than isolated pathogenic pathways. Objective: To propose a clinically grounded conceptual framework that integrates vascular, immune, and fibrotic processes into a dynamic loop model of SSc, derived from longitudinal clinical observations and contextualized within existing immunological and vascular literature. Methods: This integrative framework is informed by long-term clinical follow-up, nailfold videocapillaroscopy patterns, immune biomarker profiling, and outcome analyses reported in SSc cohorts. Observations are organized into operational domains and translated into testable predictions reflecting shifts in pathway dominance over time. Results: The proposed model conceptualizes SSc as a self-sustaining dynamic loop in which vascular injury, immune signaling, and fibrotic remodeling interact non-linearly. Capillaroscopic patterns emerge as relatively stable structural readouts of disease phase, while immune and oxidative biomarkers reflect more dynamic functional states. This framework accounts for clinical heterogeneity, variable therapeutic responses, and the limited durability of single-target interventions. Conclusions: Rather than representing a static disease entity, SSc can be understood as a dynamic system governed by shifting pathway dominance within a persistent loop architecture. This model provides a unifying structure for interpreting disease heterogeneity and supports the development of stage-adapted, combination therapeutic strategies.

Indexed as

InflammationScleroderma, SystemicBiomarkersFibrosisHumansMicroscopic AngioscopyBiomarkersdisease heterogeneitydynamic disease modelingimmune network geometrynailfold videocapillaroscopyphase-adapted therapysystemic sclerosisvascular-immune-fibrotic loop

Identifiers

PMID42148067
PMCPMC13176282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.